RT Journal Article
SR Electronic
T1 Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 47
OP 53
DO 10.1097/IGC.0b013e318234fa3a
VO 22
IS 1
A1 Bengt Sorbe
A1 Marianne Graflund
A1 György Horvath
A1 Marie Swahn
A1 Karin Boman
A1 René Bangshöj
A1 Margareta Lood
A1 Henric Malmström
YR 2012
UL http://ijgc.bmj.com/content/22/1/47.abstract
AB Objectives The purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a series of patients with advanced-stage ovarian carcinoma treated with a first-line weekly docetaxel and 3 weekly carboplatin regimen.Methods All eligible patients were treated with intravenous docetaxel (30 mg/m2) on days 1, 8, and 15, and carboplatin (area under the curve, 5) on day 1; every 21 days for at least 6 cycles.Results One hundred six patients received at least one cycle of primary chemotherapy (median, 6.0; range, 1–9), and they were evaluable for toxicity assessment. Eighty-five patients had evaluable (measurable) disease and received at least 3 courses of chemotherapy and were evaluable for clinical response rate. The overall response rate was 78.8% (95% confidence interval, 70.1%–87.5%), and the biochemical response 92.8% (95% confidence interval, 87.2%–98.4%). The median progression-free survival was 12.0 months and the median overall survival was 35.3 months. Thirty-six patients (34.0%) experienced grades 3 and 4 neutropenia, which resulted in the removal of 3 patients. Six patients (5.7%) experienced grades 3 or 4 thrombocytopenia. No patients experienced grade 3 to grade 4 sensory neuropathy. Epiphora, nail changes, and fatigue were frequently recorded nonhematologic adverse effects.Conclusions The tolerable hematologic toxicity (no need for colony-stimulating factors) and the low rate of neurotoxicity (only grades 1–2) and response rates in line with the standard 3-week paclitaxel-carboplatin regimen for advanced primary ovarian carcinoma after suboptimal cytoreductive surgery make this regimen an interesting alternative in selected patients.